Item 2.02 Results of Operations and Financial Condition.

On January 11, 2021, Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, Inc. (the "Company") disclosed certain preliminary financial information for the year ended December 31, 2020 during the Company's presentation at the 39th Annual J.P. Morgan Healthcare Conference (the "Conference") and in discussions with third parties at the Conference. Specifically, the Company disclosed its cash position of approximately $1.9 billion as of December 31, 2020 and that the Company generated approximately $122.6 million in revenue (unaudited) in the fourth quarter ended December 31, 2020, and approximately $456 million in revenue (unaudited) in the year ended December 31, 2020 from sales of EXONDYS 51® (eteplirsen) Injection and VYONDYS 53® (golodirsen) Injection. A copy of the slide presentation associated with this announcement is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2020 and its results of operations for the three months and year ended December 31, 2020. The audit of the Company's financial statements for the year ended December 31, 2020 is ongoing and could result in changes to the information in this Item 2.02.

Item 7.01. Regulation FD Disclosure.

The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01.

The slides presented by Mr. Ingram at the Conference on January 11, 2021 are furnished with this report as Exhibit 99.1, which is incorporated herein by reference.

The information in this report and Exhibit 99.1 to this report is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit No.   Description
   99.1         Sarepta Therapeutics, Inc. Presentation at the 39th Annual J.P.
              Morgan Healthcare Conference, dated January 11, 2021
    104       The cover page from this Current Report on Form 8-K of Sarepta
              Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit
              101




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses